In a separate study , published in JAMA in August 2025, the same researchers found that, across ages, GLP-1s were associated with lower risk of some obesity-related cancers, such as endometrial, ovarian, and meningioma cancers, but with an increased risk of kidney cancer, and nonsignificant changes for several other cancers
Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)
Medicare Part D Plans Participation
1 most craved food among GLP-1 users, appearing alongside the word "craving" more than any other food in the dataset